Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 40 of the 56 sources its claims cite were checked for support.
Abstract
BACKGROUND: Heart failure with preserved ejection fraction is increasing in prevalence and is associated with a high symptom burden and functional impairment, especially in persons with obesity. No therapies have been approved to target obesity-related heart failure with preserved ejection fraction. METHODS: We randomly assigned 529 patients who had heart failure with preserved ejection fraction and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or higher to receive once-weekly semaglutide (2.4 mg) or placebo for 52 weeks. The dual primary end points were the change from baseline in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating fewer symptoms and physical limitations) and the change in body weight. Confirmatory secondary end points included the change in the 6-minute walk distance; a hierarchical composite end point that included death, heart failure events, and differences in the change in the KCCQ-CSS and 6-minute walk distance; and the change in the C-reactive protein (CRP) level. RESULTS: The mean change in the KCCQ-CSS was 16.6 points with semaglutide and 8.7 points with placebo (estimated difference, 7.8 points; 95% confidence interval [CI], 4.8 to 10.9; P<0.001), and the mean percentage change in body weight was -13.3% with semaglutide and -2.6% with placebo (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001). The mean change in the 6-minute walk distance was 21.5 m with semaglutide and 1.2 m with placebo (estimated difference, 20.3 m; 95% CI, 8.6 to 32.1; P<0.001). In the analysis of the hierarchical composite end point, semaglutide produced more wins than placebo (win ratio, 1.72; 95% CI, 1.37 to 2.15; P<0.001). The mean percentage change in the CRP level was -43.5% with semaglutide and -7.3% with placebo (estimated treatment ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001). Serious adverse events were reported in 35 participants (13.3%) in the semaglutide group and 71 (26.7%) in the placebo group. CONCLUSIONS: In patients with heart failure with preserved ejection fraction and obesity, treatment with semaglutide (2.4 mg) led to larger reductions in symptoms and physical limitations, greater improvements in exercise function, and greater weight loss than placebo. (Funded by Novo Nordisk; STEP-HFpEF ClinicalTrials.gov number, NCT04788511.).
Overview
CoChat Summary
TL;DR
In STEP-HFpEF, once-weekly semaglutide 2.4 mg versus placebo in patients with heart failure with preserved ejection fraction and obesity improved heart failure symptoms/physical limitations, body weight, exercise function, a hierarchical composite outcome, and CRP over 52 weeks. Semaglutide also had fewer serious adverse events than placebo.
Key findings
- Dual primary end points: mean KCCQ-CSS change was 16.6 points with semaglutide vs 8.7 with placebo (estimated difference, 7.8 points; 95% CI, 4.8 to 10.9; P<0.001), and mean body weight changed by -13.3% vs -2.6% (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001).
- Confirmatory secondary end points: 6-minute walk distance changed by 21.5 m vs 1.2 m (estimated difference, 20.3 m; 95% CI, 8.6 to 32.1; P<0.001); hierarchical composite win ratio was 1.72 (95% CI, 1.37 to 2.15; P<0.001); CRP changed by -43.5% vs -7.3% (estimated treatment ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001).
- Safety: serious adverse events occurred in 35 participants (13.3%) with semaglutide vs 71 (26.7%) with placebo (P<0.001), driven mainly by fewer cardiac disorder events (7 [2.7%] vs 30 [11.3%]; P<0.001); discontinuation due to any adverse event occurred in 35 vs 14 participants, predominantly gastrointestinal events.
- Exploratory: adjudicated heart failure hospitalization or urgent visit occurred in 1 semaglutide participant vs 12 placebo participants (hazard ratio, 0.08; 95% CI, 0.00 to 0.42).
Methods
- Randomized, double-blind, placebo-controlled trial at 96 sites in 13 countries; 529 participants with HFpEF, BMI ≥30, LVEF ≥45%, NYHA class II–IV, KCCQ-CSS <90, and 6-minute walk distance ≥100 m were assigned 1:1 to once-weekly semaglutide 2.4 mg or placebo for 52 weeks plus 5-week follow-up.
- Dual primary end points were change in KCCQ-CSS and percentage change in body weight at week 52; confirmatory secondary end points included 6-minute walk distance, a hierarchical composite (death, heart failure events, KCCQ-CSS and 6-minute walk differences), and CRP.
- Efficacy was analyzed in the full analysis population using the treatment policy estimand; continuous end points used ANCOVA, the hierarchical composite used a win-ratio approach, and safety was analyzed in the as-treated safety population.
Limitations
- Stated in the paper: the number of non-White participants was low, which may limit generalizability; the trial was not adequately powered for clinical events such as heart failure hospitalizations/urgent visits; follow-up was limited to 1 year; specific glycated hemoglobin data were not collected beyond excluding diabetes; and SGLT2 inhibitor use was low.
- Evident from the text: the trial population was 95.8% White, median age 69 years, all with BMI ≥30, and patients with diabetes were excluded, so findings may not generalize to more diverse, younger, non-obese, or diabetes populations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
17 Valid · 2 Not valid · 4 Not checked · 90 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“growing evidence suggests that obesity and excess adiposity are not simply coexisting conditions but may play a role in the development and progression of heart failure with preserved ejection fraction. 4-8”
What the sources say
- Partly supportedcites [4] 4. Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324-31. sourceExperimental — accuracy not yet measured
The Background calls obesity a risk factor for incident heart failure, and the Discussion links severe obesity to more adverse outcomes and hospitalizations among patients who already have HFPEF. These findings support the hedged suggestion that obesity may matter beyond coexistence, but the paper does not establish a role for excess adiposity specifically in the development or progression of HFPEF; its HFPEF analysis concerns BMI and outcomes. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [5] 5. Newman AB, Lee JS, Visser M, et al. Weight change and the conservation of lean mass in old age: the Health, Aging and Body Composition Study. Am J Clin Nutr 2005; 82: 872-8. source
- Supportedcites [6] 6. Haykowsky MJ, Nicklas BJ, Brubaker PH, et al. Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction. JACC Heart Fail 2018; 6: 640-9. source
The Discussion (page not provided) states that increased adiposity promotes conditions that contribute to HFpEF pathophysiology. The Conclusions (page not provided) add that adipose deposition may have adverse consequences for HFpEF. Together, these support the citing sentence’s hedged claim that adiposity may play a role rather than merely coexist with the disease. (LLM, conf=0.88)
- Supportedcites [7] 7. Kitzman DW, Nicklas BJ. Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic/obese HFpEF. JACC Heart Fail 2018; 6: 1008-10. source
The main text explicitly says that excess adipose tissue likely plays a pivotal role in the development and progression of HFpEF. It also describes evidence linking adiposity to incident HFpEF and adverse outcomes in established HFpEF. This supports the citing sentence’s hedged claim that obesity and excess adiposity may contribute rather than merely coexist. (LLM, conf=0.94)
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Section 5 describes obesity-related changes that can lead to HFpEF. Section 5.8.1 links visceral adiposity to the risk of developing HFpEF and reports that central adiposity is associated with worse outcomes in patients who have it. Together, these passages support the hedged claim that excess adiposity may contribute to development and progression. (LLM, conf=0.92)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“growing evidence suggests that adipose tissue may play a pivotal role in the development, progression, and adverse outcomes of heart failure with preserved ejection fraction. 4-8”
What the sources say
- Partly supportedcites [4] 4. Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324-31. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports a U-shaped association between BMI and adverse outcomes in patients with HFpEF, and the paper describes obesity as a risk factor for developing heart failure generally. It does not establish a role for adipose tissue in HFpEF progression or specifically in its development; BMI is not a direct measure of adipose-tissue activity. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [5] 5. Newman AB, Lee JS, Visser M, et al. Weight change and the conservation of lean mass in old age: the Health, Aging and Body Composition Study. Am J Clin Nutr 2005; 82: 872-8. source
- Partly supportedcites [6] 6. Haykowsky MJ, Nicklas BJ, Brubaker PH, et al. Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction. JACC Heart Fail 2018; 6: 640-9. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says increased adiposity contributes to HFpEF pathophysiology and links abdominal fat to impaired exercise tolerance in older obese patients. This supports a possible role for adipose tissue, but the paper does not establish its role in HFpEF progression or in adverse clinical outcomes. (LLM, conf=0.85)
- Supportedcites [7] 7. Kitzman DW, Nicklas BJ. Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic/obese HFpEF. JACC Heart Fail 2018; 6: 1008-10. source
The paper’s main text explicitly says that excess adipose tissue likely plays a pivotal role in HFpEF development, progression, and adverse outcomes. It also identifies visceral adipose tissue as especially important in metabolic/obese HFpEF. (LLM, conf=0.95)
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Section 5.8.1 (page not provided) describes a pivotal role for visceral adipose tissue in obese HFpEF, linking it to both incident HFpEF risk and worse outcomes. Section 5.3 (page not provided) describes mechanisms by which epicardial adipose tissue may impair cardiac function and reports associations with greater disease severity and hospitalization or death. Together, these passages support the claim’s hedged wording. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Even when patients have well compensated heart failure with preserved ejection fraction and are in stable condition, they have markedly impaired objectively measured physical function. 34”
What the sources say
- Partly supportedcites [34] 34. Pandey A, Shah SJ, Butler J, et al. Exercise intolerance in older adults with heart failure with preserved ejection fraction: JACC state-of-the-art review. J Am Coll Cardiol 2021; 78: 1166-87. sourceExperimental — accuracy not yet measured
In ‘EI: A Key Manifestation of HFpEF’ (page unavailable), the review reports that objectively measured peak oxygen uptake is, on average, 35% lower in patients with HFpEF than in matched healthy controls. This supports marked impairment, but the passage does not establish that the patients were well-compensated and clinically stable. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our findings of substantial reductions in symptoms and physical limitations and improvements in exercise function that parallel a greater degree of weight loss with semaglutide than with placebo may offer insights into the long-standing controversy surrounding weight (and weight loss) in persons with heart failure. 8”
What the sources say
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“previous global clinical trial programs of agents such as SGLT2 inhibitors, sacubitrilvalsartan, and spironolactone for heart failure with preserved ejection fraction showed only modest changes in KCCQ scores (ranging from 0.5 to 2.3 points). 31-33”
What the sources say
- Partly supportedcites [31] 31. Butler J, Filippatos G, Jamal Siddiqi T, et al. Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved trial. Circulation 2022; 145: 184-93. sourceExperimental — accuracy not yet measured
The Discussion (page not available) reports modest KCCQ improvements in the TOPCAT spironolactone and PARAGON-HF sacubitril/valsartan trials, while the Results report modest improvements with the SGLT2 inhibitor empagliflozin. These passages support the overall characterization, but they do not establish the stated range of 0.5 to 2.3 points. (LLM, conf=0.86)
- Partly supportedcites [32] 32. Kosiborod MN, Bhatt AS, Claggett BL, et al. Effect of dapagliflozin on health status inpatients with preserved or mildly reduced ejection fraction. J Am Coll Cardiol 2023; 81: 460-73. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) describes the KCCQ benefit with dapagliflozin in DELIVER as modestly higher than that with empagliflozin in EMPEROR-PRESERVED, and mentions the sacubitril-valsartan PARAGON-HF trial. It does not establish the claimed 0.5–2.3-point range across those trials or report a corresponding spironolactone result. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [33] 33. Lewis EF, Kim HY, Claggett B, et al. Impact of spironolactone on longitudinal changes in health-related quality of life in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 2016; 9(3): e001937. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
45 more claims · 1 with their cited sources checked
Create a free account to see all 113 claims and every source verdict.
- Probably not a substantial claim. 33
- It may state two separate claims as one. 43
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and there is evidence that semaglutide 2.4 mg improves heart failure with preserved ejection fraction in individuals without diabetes by a potentially direct or indirect effect on epicardial adipose tissue (Kosiborod et al, 2023;Myasoedova et al, 2023).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Kosiborod et al, 2023
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both semaglutide and tirzepatide reduce the severity of heart failure with preserved ejection fraction (65, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [65]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with HFpEF and obesity (with and without diabetes), semaglutide 2.4 mg once weekly for 52 weeks improved symptoms, physical function, exercise function and bodyweight compared to placebo (STEP HFpEF and STEP HFpEF DM clinical trials) [59,91].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [59]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the STEP-HFpEF trial, semaglutide treatment in patients with obesity-related HFpEF led to significant improvements in the 6-min walk distance (6MWD) and Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), despite concurrent losses in lean mass [38].”
From Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“weight-loss interventions (eg, gastric bypass surgery and glucagon-like peptide-1 receptor agonists) can reduce the risk of incident HF and improve symptoms in patients with established HFpEF.16–20”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [19]
Experimental — accuracy not yet measured
39 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationO'Connor (2009) · doi:10.1001/jama.2009.454 · Cited by 2,173
Green, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Obokata, M., Reddy, Y. N. V., Pislaru, S. V., Melenovsky, V., & Borlaug, B. A. (2017) · Circulation · doi:10.1161/circulationaha.116.026807 · Cited by 1,179
Self-citationHeart Failure With Preserved, Borderline, and Reduced Ejection Fraction
Shah, K. S., Xu, H., Matsouaka, R. A., Bhatt, D. L., Heidenreich, P. A., Hernandez, A. F., Devore, A. D., Yancy, C. W., & Fonarow, G. C. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.074 · Cited by 1,110
Epidemiology of Heart Failure: A Contemporary Perspective
Roger, V. L. (2021) · Circulation Research · doi:10.1161/circresaha.121.318172 · Cited by 946
Kitzman, D. W., Brubaker, P., Morgan, T., Haykowsky, M., Hundley, G., Kraus, W. E., Eggebeen, J., & Nicklas, B. J. (2016) · JAMA · doi:10.1001/jama.2015.17346 · Cited by 921
Self-citationBordicchia, M., Liu, D., Amri, E.-Z., Ailhaud, G., Dessì-Fulgheri, P., Zhang, C., Takahashi, N., Sarzani, R., & Collins, S. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59701 · Cited by 872
Heart Failure With Preserved Ejection Fraction
Borlaug, B. A., Sharma, K., Shah, S. J., & Ho, J. E. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.01.049 · Cited by 742
Self-citationEvaluation and management of heart failure with preserved ejection fraction
Borlaug, B. A. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0363-2 · Cited by 675
Self-citation
Cited by
Items 801–900 of 1,639
Bøgh‐Sørensen, S., Campbell, R. T., Claggett, B. L., Lewis, E. F., Docherty, K. F., Lee, M. M. Y., Lindner, M., Biering‐Sørensen, T., Solomon, S. D., & Platz, E. (2025) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuaf067 · Cited by 6
Crispino, S. P., Nusca, A., Ferro, A., Cricco, R., Ciancio, M., Segreti, A., Cavallari, I., Sabatino, M., Potena, L., Ussia, G. P., et al. (2025) · Biomolecules · doi:10.3390/biom15111574 · Cited by 6
“Despite these early successes, the role of GLP-1RAs in the standalone HF management is less well defined In HFpEF, semaglutide and tirzepatide have demonstrated improvements in symptoms, functional capacity, and weight loss, particularly in patients with obesity-related phenotypes [19,20].”
Zhang, H., Xu, H., Zhou, F., Azam, T., Samman, S., Binder, P., Nguyen, B. Y., Cartwright, E. J., Müller, O. J., Hille, S. S., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.035302 · Cited by 4
“23,24 This study revealed the cardioprotective role of Pak2 through the ER signaling pathway in HFpEF, providing a new insight into potential therapeutic target.”
Diallo, A., Carlos‐Bolumbu, M., Duc, P., & Galtier, F. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103506 · Cited by 4
Dhont, S., Ferreira, S. M., Galloo, X., Martens, P., Meekers, E. M., Tartaglia, K., Deferm, S., Herbots, L., Müllens, W., Verbrugge, F. H., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.05.019 · Cited by 3
Sattar, N., Weerakkody, G. J., McGuire, D. K., Kosiborod, M. N., Lee, M. M. Y., Welsh, P., Pearson, E. R., Wiese, R. J., Duffin, K., Wilson, J., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.072889 · Cited by 6
Self-citationKaracabeyli, D., & Lacaille, D. V. (2026) · Rheumatology · doi:10.1093/rheumatology/keag147 · Cited by 4
“Subsequently, the STEP (Semaglutide Treatment Effect in People with Obesity)-HFpEF, STEP-HFpEF DM and SUMMIT trials evaluated the effects of semaglutide and tirzepa-tide, respectively, in adults with obesity and HFpEF [53, 60, 61].”
The Hidden Price of Plenty: Oxidative Stress and Calorie-Induced Cardiometabolic Dysfunction
Komić, L., Kumrić, M., Komic, J., Tomičić, M., Kurir, T. T., Grahovac, M., Mornar, M., Rušić, D., Bukić, J., & Božić, J. (2025) · Life · doi:10.3390/life15071022 · Cited by 5
“…the incidence of major adverse cardiovascular events, including cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, as well as heart failure composite outcomes, defined as cardiovascular death, hospitalization, or emergency room visits for heart failure [154,155,159].”
Body Mass Index, Clinical Outcomes, and Mortality in Heart Failure
Sunderland, N. P., Asselin, G., Henry, A., Nelson, C. P., Perreault, L. L., Asselbergs, F. W., Boersma, E. H., Cappola, T. P., Chazara, O., Chutkow, W. A., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.02.5093 · Cited by 6
Pozzi, A., Spoladore, R., Iorio, A., Corrado, G., & D’Amario, D. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10585-0 · Cited by 5
Samanidou, V., Tsamis, K., Ceasovschih, A., Koufakis, T., Patoulias, D., Rizos, E. C., Rizzo, M., Milionis, H. J., & Barkas, F. (2026) · Journal of Central Nervous System Disease · doi:10.1177/11795735261444425 · Cited by 4
Amici, F., Ciarlo, C., Abumusallam, J., Kravitz, M., Weber, A.-R., Meister, H., & Li, Z. (2024) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2023-0029 · Cited by 3
Heart Failure With Preserved Ejection Fraction
Cannata, A. N., Bromage, D. I., Piper, S. E., & McDonagh, T. A. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.05.017 · Cited by 3
The Cardiovascular Benefits of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
Kallash, M., & Frishman, W. H. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000970 · Cited by 4
Current Challenges for the Diagnosis of HFpEF and Possible Simplification of the Diagnostic Approach
Bernardi, M., Golino, M., Spadafora, L., Sarto, G., Forte, M., Simeone, B., Rocco, E., Valenti, V., Schiavon, S., Esposito, A., et al. (2025) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001755 · Cited by 3
Sindone, A. P., Abhayaratna, W. P., Chan, A., Leung, M., Hopper, I., Amerena, J. V., Pasquale, C. G. D., Burdeniuk, C., Coats, A. J. S., & Atherton, J. J. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.08.010 · Cited by 6
Self-citationInsights into Myocardial Fibrosis in Advanced Chronic Kidney Disease Using Human Tissue
Mondal, N. K., & Walther, C. P. (2023) · Kidney360 · doi:10.34067/kid.0000000000000285 · Cited by 3
“8 Obesity, highly prevalent in the US CKD population, is a cause of myocardial fi brosis, and treat-ment with glucagon-like peptide-1 receptor agonists seems to improve cardiac function, 9 possibly in part through preventing fi brosis.”
BackgroundEmpowering European hospital pharmacists in the face of heart failure
Defieuw, L., Hias, J., Karapinar‐Çarkit, F., et al. (2024) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2023-004068 · Cited by 3
Nalbandian, M., Lone, J. B., Moal, E. L., Kim, I., Jeuris, K., Li, Y. K., Kraft, P. E., Zhao, M., Koleckar, K., Zhang, Z., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2606533123 · Cited by 10
“In addition to their metabolic effects, these agents offer cardio-protective (12) and renal benefits (13), which explains their growing appeal in treating obesity as a systemic disease.”
Elbatreek, M. H., Li, Z., Yu, X., Gehred, N., Gromova, T., Chen, J., Muraoka, N., Jensen, M. B., Kartha, V. K., Carrico, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.26.678829 · Cited by 3
Self-citationLong-Term Trajectories of Left Heart Geometry, Mechanics, and Oxygen Demand After Bariatric Surgery
Grymyr, L. M. D., Nadirpour, S., Gerdts, E., Nedrebø, B. G., Matre, K., & Cramariuc, D. (2025) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.012367 · Cited by 3
What the SELECT trial of semaglutide means for clinicians
Sattar, N. A., Lee, M. M. Y., & McGuire, D. K. (2024) · Nature Medicine · doi:10.1038/s41591-024-03013-7 · Cited by 4
New COST Action ‘EUropean network to tackle METAbolic alterations in HEART failure’ (EU-METAHEART)
Maack, C., Vilahur, G., Ruiz‐Meana, M., & Hausenloy, D. J. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae457 · Cited by 4
Giugni, F., Yang, Y., Claggett, B. L., Lamberson, V., Solomon, S. D., Lutsey, P. L., Kitzman, D. W., Ndumele, C. E., Mosley, T. H., Chang, P. P., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.02.029 · Cited by 3
Self-citationIncretin-Based Anti-obesity Medications in Polycystic Ovary Syndrome: The Evidence Map
Jensterle, M., & Janež, A. (2026) · Drugs · doi:10.1007/s40265-026-02325-x · Cited by 5
Putting More Weight on Obesity Trials in Heart Failure
Harrington, J., Sattar, N. A., Felker, G. M., Januzzi, J. L., Lam, C. S. P., Pagidipati, N. J., Pandey, A., Spall, H. G. C. V., & McGuire, D. K. (2024) · Current Heart Failure Reports · doi:10.1007/s11897-024-00655-z · Cited by 3
Cotter, G., Davison, B. A., Biegus, J., Pagnesi, M., Metra, M., Butler, J., Chioncel, O. D., Ponikowski, P. P., & Mebazaa, A. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.12.015 · Cited by 3
Self-citationKumar, S. R., Anderson, J. E., Coviello, A. D., Lopez-Jimenez, F., & Bakris, G. L. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102465 · Cited by 4
Valério, C. M., Saraiva, J. F. K., Valente, F., van de Sande‐Lee, S., Rocha, V. Z., Rached, F. H., Drager, L. F., Halpern, B., Júnior, W. S. D. S., Trujilho, F. R., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01954-8 · Cited by 11
Safety and Efficacy of Semaglutide in Type 2 Diabetes Patients: A Real-World Study
Aneja, P., Bhalla, G., & Jain, A. (2025) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_48_24 · Cited by 3
Role of Anti-Obesity Drugs in Heart Failure Regardless of Ejection Fraction
Butler, J., Arshad, M. S., & Khan, M. S. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3224 · Cited by 3
Self-citationDesigning Next-Generation Cardiometabolic Outcome Trials for Obesity Medicines
Platz, E., Peikert, A., Bozkurt, B., der Schueren, B. V., Butler, J., Lingvay, I., McGuire, D. K., Zannad, F. M., & Sattar, N. A. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.01.013 · Cited by 3
Self-citationManagement of Ischemic Heart Disease in Patients With Heart Failure
Mielniczuk, L. M., Ahmad, T., Borovac, J. A., Brown, K., Cooper, L. B., Fida, N., Hochman, J. S., Al-Lamee, R. K., Lawton, J. S., Narang, N., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102731 · Cited by 5
Self-citationDong, H., Hu, P., Wang, J., & Lu, N. (2024) · Biological Trace Element Research · doi:10.1007/s12011-024-04287-1 · Cited by 3
“Body mass index (BMI) was calculated as: weight (kg)/the square of height (m 2 ) [30].”
Treatment of Obesity in Heart Failure
Bozkurt, B. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.05.016 · Cited by 3
Enhancing Patient Outcomes: Prioritizing SGLT2is and GLP-1RAs in Diabetes with CVD
Koh, G. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0096 · Cited by 3
Evolving Role of GLP-1 Therapies in Liver Disease
Lindsay, M., Arndt, G., Wieland, A. C., & Jensen, T. (2025) · Current Gastroenterology Reports · doi:10.1007/s11894-025-00988-2 · Cited by 3
“…(Major Adverse Cardiovascular Events), which includes cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and hospitalization for unstable angina as well as outcomes in Heart Failure patients for those with and without T2D as well as renal disease protection in T2D [11–14].”
Stenlid, R., Amrani, S. E., Cerenius, S. Y., Aydın, B. K., Manell, H., Mörwald, K., Lischka, J., Gomahr, J., Pixner, T., Ciba, I., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02882-7 · Cited by 5
“Obesity is also associated with other cardio-vascular diseases such as heart failure with preserved ejection fraction (HFpEF), atrial fibrillation, hypertension, atherosclerosis, and coronary heart disease [5–8].”
Assessing Medical Therapy Optimization in Cardiovascular-Kidney-Metabolic Clinical Trials
Bhatt, A. S., Oliveira-Gomes, D. D., Fiuzat, M., Vaduganathan, M., HAMO, C. E., Stockbridge, N., Butler, J., Psotka, M. A., Abraham, W. T., McGuire, D. K., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102727 · Cited by 3
Self-citationTherapy for HFpEF: A step forward brings new hope for people with obesity and diabetes
Lim, L., & Khunti, K. (2024) · Med · doi:10.1016/j.medj.2024.06.011 · Cited by 4
Bie, E. M. D. D. D., Correa‐Jaque, P., Jones, R. J., Bogaard, H. J., Chan, J. T. N., Church, C., Coghlan, G., Gaur, A., Ghio, S., Ghofrani, H. A., et al. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202412-2393oc · Cited by 5
Otmani, Z., Elsayed, H. A., Yassin, M. N. A., Saihi, M. J., Aldemerdash, M. A., Alzawahreh, A., Hassan, A., Alahmed, F. B., Gonnah, A. R., & Abdelaziz, A. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000925 · Cited by 4
Athinarayanan, S. J., Phinney, S. D., Adams, R. N., Volek, J. S., Thurmond, D. C., McKenzie, A. L., Roberts, C. G. P., Ratner, R. E., Krauss, R. M., & Fonseca, V. A. (2026) · Endocrine Research · doi:10.1080/07435800.2026.2659579 · Cited by 3
Pham, H. N., Ibrahim, R., Abdelnabi, M. H., Bcharah, G., Mahmoud, A., Allam, M., Farina, J., Lee, J. Z., Singh, A., Ayoub, C., et al. (2025) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcaf135 · Cited by 6
Florescu, A. G., Pucerea, S. A., Floria, M., Rusu, E., Cuiban, E., Jinga, M., Galrinho, R. D., & Stanciu, S. M. (2025) · Romanian Journal of Military Medicine · doi:10.55453/rjmm.2025.128.6.9 · Cited by 8
Wan, Y., Ma, N., Zhang, Y., et al. (2025) · Langmuir · doi:10.1021/acs.langmuir.4c03956 · Cited by 3
Ilonze, O. J., & Mazimba, S. (2024) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-024-00755-4 · Cited by 5
“There were significant improvements in KCCQ clinical summary score, 6-min walk distance, C-reactive protein, and N-terminal pro-natriuretic peptide for the semaglutide group, who had a mean percent body weight change of −13.3%, vs. −2.6% with placebo [61].”
InfluentialSolanki, A., Kamrava, M. R., Posadas, E. M., Freedland, S. J., Ballas, L., Sandler, H. M., Merz, C. N. B., Atkins, K. M., & Nikolova, A. (2024) · Cancer · doi:10.1002/cncr.35285 · Cited by 8
A case series of incidents reported to webAIRS relating to glucagon-like peptide 1 agonist use
Lam, C. Y., Lin, D., & Endlich, Y. (2025) · Anaesthesia and Intensive Care · doi:10.1177/0310057x241311597 · Cited by 4
“54,55 As such, there is a need to ensure that GPs are well-educated regarding the comprehensive and specific implications of these medications prior to prescribing but also of the possible perioperative implications.”
Akbar, U. A., Mondal, A., Vorla, M., Alruwaili, W., Lacoste, J. L., Thyagaturu, H. S., Shafique, N., Shakeel, S., Taha, A., & Balla, S. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.05.004 · Cited by 3
van Essen, B. J., Dan, N. A. E., Tharshana, G. N., Kaur, P., Emmens, J. E., Ouwerkerk, W., Gansevoort, R. T., Bakker, S. J. L., de Boer, R. A., Damman, K., et al. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133914 · Cited by 5
Potential therapies for obesity management: Exploring novel frontiers
Chand, S., Dikkatwar, M. S., Varghese, T. P., Singh, R., Sah, S. K., Sutar, A. S., Biswas, J., & Shandily, S. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102382 · Cited by 4
Feldman, J. M., Frishman, W. H., & Aronow, W. S. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000776 · Cited by 3
Spetko, N., Scott, C. H., Angell-James, C. E. M., Cassidy, M. A., Alwani, T., Mukherjee, M., Nagueh, S. F., & Strom, J. B. (2026) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2026.01.006 · Cited by 6
GLP-1 Receptor Agonists in Heart Failure With Reduced Ejection Fraction?
Litwin, S. E., Drazner, M. H., & Russo, A. M. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102642 · Cited by 3
Adropin protects against cardiac remodeling and metabolic dysfunction in a mouse model of HFpEFPreprint
Mushala, B. A. S., Stoner, M. W., Sharifi‐Sanjani, M., Manning, J. R., Bugga, P., Bhattarai, N., McMahon, B., Vandevender, A. M., Mullett, S. J., Kaufman, B. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.03.652038 · Cited by 3
Prevalence and Clinical Implications of Excess Adiposity in Group 1 Pulmonary Hypertension
Reddy, Y. N. V., Frantz, R. P., Hemnes, A. R., Hassoun, P. M., Horn, E. M., Leopold, J. A., Rischard, F. P., Rosenzweig, E. B., Hill, N. S., ERZURUM, S. C., et al. (2025) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.013591 · Cited by 6
Self-citationWang, K., Zhang, H., & Chen, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-17483-3 · Cited by 5
“Recent randomized controlled clinical trials, namely STEP-HFpEF 47 STEP-HFpEF DM 48 and SUMMIT 49 have demonstrated that treatment with semaglutide or tirzepatide decreased the risk of adverse events in patients with HFpEF and markedly reduced systemic inflammation.”
Agrawal, S. P., Tated, R. C. P., Maheta, D., & Aronow, W. S. (2025) · Minerva Medica · doi:10.23736/s0026-4806.25.09656-9 · Cited by 5
Malahfji, M., & Al-Mallah, M. H. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.118523 · Cited by 3
Marques, P. S., & Ferreira, J. P. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf198 · Cited by 3
Du, F., Ospina, N. S., Chen, Y., Brito, J. P., Liu, Q., Schmidt, S., McCoy, R. G., Cicali, B., Shao, H., & Jiao, T. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02971-7 · Cited by 5
Obesity and Heart Failure: A New Era Begins
Borlaug, B. A., & Kindel, T. L. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.02.009 · Cited by 3
Self-citationMochel, J. P., Ward, J. L., Blondel, T., Kundu, D., Merodio, M. M., Zemirline, C., Guillot, E., Giebelhaus, R. T., de la Mata, A. P., Iennarella‐Servantez, C. A., et al. (2023) · Research Square · doi:10.22541/au.170022092.29999283/v1 · Cited by 2
Update on clinical heart failure trials
Hoevelmann, J., Tokcan, M., Kulenthiran, S., Abdin, A., Viljoen, C. A., & Böhm, M. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02784-4 · Cited by 2
“In both populations, improvements in these patient-reported outcomes were associated with reductions in CRP and IL-1 levels [17, 18].”
Lu, H. Y., Kosztin, A., Claggett, B. L., Foà, A., Pabón, M. A., Desai, A. S., Jhund, P. S., Henderson, A. D., Merkely, B. P., Lam, C. S. P., et al. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2026.0682 · Cited by 3
Self-citationAhmad, Y., Wasan, R., Perchik, J. D., & Nanda, N. C. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15124430 · Cited by 2
“By the end of the study period, participants in the semaglutide treatment group had decreased symptom burden and increased six-minute walk distance [159].”
Castro, C., Delwarde, C., Shi, Y., & Roh, J. D. (2025) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2024.15 · Cited by 3
Disse, E., Aron‐Wisnewsky, J., Jacobi, D., Clément, K., Laville, M., Gauthier, C., Pattou, F. N., Molleville, J., Akerib, M., Jubin, L., et al. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101625 · Cited by 3
Yu, C., Yang, H., Zhang, B., Chen, S., Yang, S., Li, F., Zhu, W., Zhai, B., Wu, T., Zhao, S., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-095382 · Cited by 3
Stefanović, M., Trifunović, D., Mladenović, Z., Tadić, S., Apostolovic, S. R., Petrović, O., Vranić, I., Milic, G., Milovančev, A., Krljanać, G., et al. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133651 · Cited by 2
Lewsey, S. C., Martyn, T., Blumer, V. L., Brownell, N. K., Denfeld, Q. E., Dunlay, S. M., Goyal, P., Halloway, S., Matlock, D., Vardeny, O., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001437 · Cited by 7
Seidel, D. U., & Bode, S. (2025) · HNO · doi:10.1007/s00106-025-01653-w · Cited by 3
“Darüberhi-naus senken sie das Risiko für kardiovas-kuläre Erkrankungen durch Reduktion von oxidativem Stress, Hemmung entzündli-cher Prozesse und Verbesserung der Herz-funktion [14, 15, 23].”
Restricted Time Win Ratio: From Estimands to Estimation
Wang, T., Li, Y., & Qu, Y. (2024) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2024.2332675 · Cited by 6
“…of the aforementioned primary endpoints were reevaluated in the order of CV death, the number of combined nonfatal CV events, time to first combined CV events, and at least 0.3% HbA1c improvement, similar to the hierarchical composite endpoint used in STEP-HFpEF study (Kosiborod et al. 2023).”
InfluentialCardiovascular-Kidney-Metabolic Health
Solomon, M., Claudel, S. E., & Verma, A. (2025) · Cardiology Clinics · doi:10.1016/j.ccl.2025.03.001 · Cited by 4
A New Epoch in Treating Diseases of the Heart
Purnell, J. Q., & Camacho, S. A. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.01.007 · Cited by 2
Riemma, M. A., Madonna, G., Mele, E., Conte, E., Telesca, M., Palma, G. D., Kutryb-Zając, B. A., Cicala, C., Imbrici, P., Liantonio, A., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1720123 · Cited by 2
Dilaver, R. G., Afşar, R. E., Crescenzi, R. L., Gamboa, J. L., & Ikizler, T. A. (2025) · medRxiv · doi:10.1101/2025.03.19.25324266 · Cited by 2
Onboarding obesity management in cardiovascular care: A cardiologist's guide to latest advances
Schiele, F., Diévart, F., Jacobi, D., Angoulvant, D., Czernichow, S., Puymirat, É., Sabouret, P. F., & Aboyans, V. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.100987 · Cited by 2
“In addition, the STEP HFpEF study demonstrated semaglutide improved Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) by 7.8 points, increased 6-minute walking distance by 20.3 m, and reduced body weight by 10.7 % compared to placebo [42 – 44].”
InfluentialTentolouris, A., Filippatos, C., Tepetes, N.-I., Gavriatopoulou, M., Terpos, E., Briasoulis, Α., Stamatelopoulos, K. S., & Filippatos, T. D. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70841 · Cited by 4
“GLP- 1-based therapies have also been investigated in HF populations, showing improvements in symptoms alongside meaningful weight loss in patients with HF with preserved ejection fraction [33, 34].”
Leite, A. R., Dias, J., Godinho, T., Correia-Chaves, J., Borges‐Canha, M., Lourenço, I. M., Leite-Moreira, A. F., & Neves, J. S. (2024) · Endocrinology Insights · doi:10.1159/000541442 · Cited by 5
“In patients with obesity-related HFpEF, semaglutide improved exercise function and quality of life [120, 121].”
Tanacli, R., Trivedi, R. K., Tajdini, M., Jani, V., Tian, J., Hahn, V. S., Vaishnav, J., Damluji, A. A., Gerstenblith, G., Buta, B. J., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102560 · Cited by 3
Self-citationHeart Failure With Preserved Ejection Fraction Across the Spectrum of Body Mass Index
Harrington, J., Giczewska, A., Rao, V. N., Fudim, M., Peters, A. E., Chrischilles, E. A., Jones, W. S., May, H. T., Steinberg, B. A., VanWormer, J. J., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102768 · Cited by 4
From the Editors: New concepts in obesity and cardiovascular disease
Duell, P. B., & Maki, K. C. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.11.003 · Cited by 2
Kushner, P. R., Campos, C., King, A., Kruger, D. F., & Morales, J. (2025) · Clinical Diabetes · doi:10.2337/cd25-0037 · Cited by 3
Fu, L., Du, Y., Yang, P., Hu, J., & Chen, Q. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.02.022 · Cited by 2
Advancing Cardiorenal Interaction: From Pathophysiological Paradigms to Novel Therapeutic Strategies
Wei, L., He, P., Gao, J., Huang, L., Zhao, L., Zhang, R., Ning, X., & Sun, S. (2025) · Kidney Diseases · doi:10.1159/000548367 · Cited by 2
“Once-weekly semaglutide for 52 weeks led to greater improvements in symptoms, exercise function, and greater weight loss than placebo [100].”
Zakeri, R., & Nabeebaccus, A. (2026) · Clinical Medicine · doi:10.1016/j.clinme.2026.100608 · Cited by 4
Lehenbauer, K. S., Nelson, A. J., Nodari, S., Sverdlov, A. L., & Harrington, J. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10579-y · Cited by 5
Embracing an era of targeted combination therapy for heart failure with preserved ejection fraction
Shoji, S., Greene, S. J., & Mentz, R. J. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10432-8 · Cited by 3
Tom-Ayegunle, K., Tom-Ayegunle, O., Okoye, S., Chukwuemeka, U., Adeyina, T., Babarinde, A. O., & Eleam, U. (2026) · Cureus · doi:10.7759/cureus.100947 · Cited by 5
“GLP-1 RAs should be strongly considered for cardiovascular risk reduction in non-diabetic obesity with established cardiovascular disease (NNT 48, strongest evidence from SELECT) [11], multiple cardiovascular risk factors (NNT 250), or HFpEF, particularly in women [14, 19].”
InfluentialAlebna, P. L., Martey, S., Mehta, A., Lavie, C. J., & Carbone, S. (2025) · Current Cardiology Reports · doi:10.1007/s11886-025-02333-5 · Cited by 3
“However, in patients with obesity and chronic placebo [51].”
Diuretic Combination Therapy in Acute Heart Failure: An Updated Review
Villaschi, A., Pellegrino, M., Condorelli, G., & Chiarito, M. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128316596240625110337 · Cited by 5
Impact of glucagon-like peptide-1 receptor agonists on hypertension management: a narrative review
Oliveira-Gomes, D. D., Pingili, A., Inglis, S. S., Mandras, S. A., Loro-Ferrer, J. F., & daSilva‐deAbreu, A. (2025) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001225 · Cited by 2
Ahmed, H. M., Rehman, U. U., Owais, M. A., & Hamza, M. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.04.046 · Cited by 3
Cardiovascular Risk Reduction With GLP-1 RA Drugs
Pigeyre, M., & Gerstein, H. C. (2026) · Circulation · doi:10.1161/circulationaha.126.079319 · Cited by 4
Diagnose und Therapie der Herzinsuffizienz mit erhaltener Ejektionsfraktion
Soltani, S., & Bauersachs, J. K. (2025) · Herz · doi:10.1007/s00059-025-05327-9 · Cited by 2
Harrington, J. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10408-8 · Cited by 2
Manon, M.-F., Pieronne-Deperrois, M., Bonnard, B., Coralie, F., Kong, L., Amhrae, N. D., Nicol, L., Morchid, S., Renet, S., Dumesnil, A., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02935-x · Cited by 2
“…cardiovascular function in patients with HF. Recently, the trials on Semaglutide Treatment Effect in People with obesity and HFpEF (STEP-HF) [14], with or without diabetes mellitus (STEP-HF-DM) [15] evaluated the benefits of facilitating weight loss during a one-year treatment with a…”
Of Endpoints and Equipoise: Reforming Clinical Trials in Colorectal Polyp Resection
Smith, Z. L., Forbes, N., Madhavan, S., Pohl, H., Schauer, J. M., Steinbrück, I., & Renteln, D. A. V. (2025) · Current Gastroenterology Reports · doi:10.1007/s11894-025-01013-2 · Cited by 2
Metadata
- Authors
- Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., Shah, S. J., Treppendahl, M. B., Verma, S., Abhayaratna, W., Ahmed, F. Z., Chopra, V., Ezekowitz, J., Fu, M., Ito, H., Lelonek, M., Melenovsky, V., Merkely, B., Núñez, J., Perna, E., Schou, M., Senni, M., Sharma, K., Van der Meer, P., von Lewinski, D., Wolf, D., & Petrie, M. C.
- Affiliations
- University of Copenhagen (DK)
- From the Department of Cardiovascular Disease, Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City School of Medicine, Kansas City (M.N.K.); Novo Nordisk, Søborg (S.Z.A., S.R., G.K.H., M.L.L., D.V.M., M.B.T.), and the Department of Cardiology, Herlev-Gentofte Hospital, University of Copenhagen, Herlev (M. Schou) — both in Denmark; the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.); Baylor Scott and White Research Institute, Dallas (J.B.); the Department of Medicine, University of Mississippi, Jackson (J.B.); Diabetes Research Centre, University of Leicester, and National Institute for Health and Care Research Leicester Biomedical Research Centre (M.D.), Leicester, the Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester (F.Z.A.), and the School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (M.C.P.) — all in the United Kingdom; the Department of Cardiovascular Medicine ...
- ORCID
- Kosiborod, Mikhail N.
- Borlaug, Barry A.
- Butler, Javed
- Davies, Melanie
- Hovingh, G. Kees
- Kitzman, Dalane W.
- Shah, Sanjiv J.
- Verma, Subodh
- Abhayaratna, Walter
- Ahmed, Fozia Z.
- Chopra, Vijay
- Ezekowitz, Justin
- Fu, Michael
- Ito, Hiroshi
- Lelonek, Małgorzata
- Merkely, Bela
- Núñez, Julio
- Perna, Eduardo
- Schou, Morten
- Senni, Michele
- Sharma, Kavita
- Wolf, Dennis
- Petrie, Mark C
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-09-21
- Volume
- 389
- Issue
- 12
- Pages
- 1069-1084
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4386154055
- Cited by
- 1,669
- References
- 41
- Citations by year
- 2026: 548 · 2025: 597 · 2024: 461 · 2023: 61
- FWCI
- 327.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Research Explorer (The University of Manchester) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- semaglutide, heart failure with preserved ejection fraction, obesity, weight loss, Kansas City Cardiomyopathy Questionnaire, 6-minute walk distance, C-reactive protein, GLP-1 receptor agonists, heart failure events, body weight, symptom burden
- MeSH terms
- Semaglutide, Glucagon-Like Peptides, Heart Failure, Humans, Obesity, Stroke Volume
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.